and total oxygen content (4) with real-time tracking. Table 1 (4-11) presents CNHM systems, characteristics, and intended uses.
Devices may be limited to adults and children weighing more than 30 kilograms (7)-pediatric intensivists should proceed with caution. Notable is the limited range of hemoglobin measurements. Lower bounds of 7 to 8 g/dL could compromise transfusion decisions in critically ill trauma, emergency, and burn surgery patients (12) , for whom it would be wise to use CNHM strictly according to FDA-approved intended uses and only as trend monitors. In fact, Frasca et al. (1) present convincing analysis of trend data that serves to validate this purpose for patients who are not actively bleeding.
Other investigators have mixed recent findings. In an ED study, Gayat et al. (13) concluded, "Results from this widely available noninvasive point-of-care hemoglobin monitoring device were systematically biased and too unreliable to guide transfusion decisions." and "…use of the Masimo Radical-7 Pulse CO-Oximeter would lead to 13% error in terms of transfusion decisions." Miller et al. (14) found, "…SpHb [CNHM] may not be as accurate as clinically necessary in some patients." and "When perfusion diminishes, SpHb underestimates true Hb, so it should not be used to determine the need for blood transfusions without validation using a direct measurement methodology." Causey et al. (15) observed a correlation of the Masimo Radical-7 SpHb Station versus laboratory hemoglobin measurements of 0.77 (P < 0.001) with a mean difference of 0.29 g/dL (95% CI, 0.08-0.49) and reasoned "…the device SpHb to have clinically acceptable accuracy during most types of surgery including those with significant blood loss-…44% of patients in the study sustained significant intraoperative blood loss, the patient population for which the device would prove to be most useful."
Frasca et al. (1) recommend additional study to evaluate the merits of CNHM in hemorrhaging patients, early detection of bleeding, and monitoring of blood management. We recommend also validation of performance in patients with anemia, hemodilution, severe hypotension, low tissue perfusion, and restrictive blood transfusion thresholds (hemoglobin ≤ 7 g/dL). Noting limitations, the authors (1) state, "…less than 10% of measures were performed in patients with hemoglobin concentration below 8 g/dL." In fact, data sets presented to the FDA typically lack these low range observations (6-8).
The litany of confounders plaguing pulse (co)-oximetry is extensive [e.g., ambient light, bilirubin, hemoglobin variants, intravascular dyes, patient motion, pressure necrosis, sensor malpositioning and type, skin temperature readings (see recall: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=97029), and venous congestion]. Investigators point to potential technical issues with hemoglobin monitoring, such as edema and multiple physiological changes that render optical spectroscopic tissue parameters inaccurate or impossible to track (16) , inconsistent inter-individual path length and high tissue lipid content that challenge calibration assumptions (17) , and blood volume depletion that alters optical scattering and absorption characteristics (18) .
Clearly, the use of CNHM in critically ill patients shows strong merit. Trend monitoring may be a useful alternative to serial in vitro testing, especially when reducing iatrogenic blood loss, conserving patient blood volume, enhancing the timeliness of decision-making, and improving the cost-effectiveness of transfusions. Thus, Frasca et al. (1) imply a disruptive shift toward continuous measurement at the point of need (19) and a subtle, but interesting drift in the standard of care for hemoglobin determinations.
The concept of standard of care is based on Vaughn v. Menlove (1837), wherein the judge instructed the jury to reason whether the defendant "proceed[ed] with such reasonable caution as a prudent man would have exercised under such circumstances." Before declaring that CNHM has changed the standard of critical care, reasonable caution dictates a) the technology be improved and validated better in the low range (< 8 g/dL); b) continuous validation occurs during dynamic, rather than static, hematological conditions; and c) multicenter investigators provide evidence of improved decision-making and outcomes related to early detection of bleeding episodes and transfusion practices.
Whether or not these challenges are fully met, CNHM has the potential to reduce the medical-financial burden of repeated or unnecessary in vitro laboratory hemoglobin measurements, help conserve patient blood volume by reducing iatrogenic losses, avoid the risks of anemia, optimize intraoperative transfusions, and even enhance care in low-resource settings, such as epidemic Dengue hemorrhagic fever outbreaks where erythrocyte repletion based on hourly spun hematocrits can be partially or completely supplanted by following trends in hemoglobin. Therefore, future impact is high. 
